Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP10 | P09238 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538829 | 0.84 | ALDH1A1 (0.46) | KDM4EHSD17B10USP2ALDH1A1MAPT | |
| SCHEMBL8182461 | 0.81 | SMN1; SMN2 (0.52) | KDM4EHSD17B10ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12233448 | 0.78 | MET (0.34) | ALDH1A1SMN1; SMN2ACACBMAPK1 | |
| SCHEMBL12257867 | 0.72 | ALDH1A1 (0.34) | KDM4EHSD17B10USP2ALDH1A1MAPT | |
| SCHEMBL2536394 | 0.67 | MAPT (0.35) | ALDH1A1MAPTSMN1; SMN2KMT2AACACB | |
| SCHEMBL12233411 | 0.67 | KDM4E (0.35) | KDM4EMAPTSMN1; SMN2KMT2ATSHR | |
| SCHEMBL12233436 | 0.65 | MEN1 (0.38) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL8189626 | 0.65 | TSHR (0.55) | KDM4EHSD17B10USP2ALDH1A1MAPT | |
| SCHEMBL2536982 | 0.64 | CA12 (0.53) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL8195252 | 0.63 | ACACB (0.50) | ALDH1A1MAPTSMN1; SMN2TSHRACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | KDM4E 3538/4885HSD17B10 616/4885USP2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.